Illumina Launches TruSight® Tumor OncoPanel
September 29 2015 - 6:30AM
Business Wire
Focused Panel Sets the Groundwork for Illumina
Oncology Program
Illumina, Inc. (NASDAQ:ILMN) today announced it has launched
TruSight® Tumor 15, a next-generation sequencing (NGS) panel
designed to identify sequence variants in 15 genes commonly
associated with marketed therapeutics. TruSight Tumor 15 is
optimized for low input DNA from tissue preserved in formalin and
paraffin.
“In 2014, Illumina catalyzed the Actionable Genome Consortium
(AGC), bringing together thought leaders to define the standards
and content for NGS panels intended for use in oncology
applications,” said Francis deSouza, President of Illumina. “The
TruSight Tumor panel represents the first product, intended for
research use only, based on the initial standards defined by the
AGC and pharma partners, enabling researchers to advance the
application of NGS in this important field.”
The new sequencing panel is optimized for damaged and degraded
formalin-fixed, paraffin embedded (FFPE) tumor samples, enabling
low frequency somatic variant detection from limited nucleic acid
inputs. When paired with the Illumina MiSeq® system, the panel
delivers high-quality sequencing with key content and features
needed for tumor analysis in translational research.
Illumina is committed to collaborating with pharma partners, the
Actionable Genome Consortium, regulatory agencies and key opinion
leaders to establish best-practices and consensus standards in NGS
testing.
“Tumor biopsies are collecting ever smaller amounts of cancer
tissue and the fixation and preservation of the material results in
degraded DNA. The challenge for scientists has been to get
sufficient intact DNA to efficiently identify the key genetic
drivers,” said John Leite, Ph.D., Vice President of Oncology at
Illumina. “This new panel is designed to reduce the resource burden
on small and medium-sized labs by offering a simple, accurate and
fast solution that addresses tissue considerations on the front end
and provides streamlined analytics on the back end.”
Dr. Jamie Platt, Vice President of Genomic Solutions at
Molecular Pathology Laboratory Network, Inc., evaluated the product
in beta testing and said the panel’s simplicity and ease of use
makes it well-suited for translational labs, “The value and appeal
of next-generation sequencing is the potential to consolidate
traditionally iterative tumor analyses. Our evaluation of the new
TruSight Tumor 15, with its streamlined library prep and sequencing
workflow, gives us confidence that this application is ideal for
deployment. Even our most challenging samples produced results,
including those with low nucleic acid inputs, giving us assurance
we can analyze our most precious specimens.”
TruSight Tumor 15 offers a sample-to-data solution for
research of common somatic variants.
- Simple sample-to-data workflow
optimized for the MiSeq instrument will drive greater lab
operational efficiency by replacing the cost and resource intensive
practice of iterative single gene analysis.
- Focused gene content was informed by
pharmaceutical partners, an independent consortia of key opinion
leaders and the needs of pharmaceutical clinical researchers to
identify relevant somatic variants in common solid tumors.
- Streamlined multiplex PCR-based library
prep method, with limited hands on time, produces high-quality data
in approximately 36 hours from extracted DNA to result.
- Highly sensitive assay detects somatic
mutations at 5 percent variant frequency and maximizes sample
success with 20 ng of DNA isolated from FFPE samples.
TruSight Tumor 15 is available for order now and will ship in Q4
2015. For more information, visit
www.illumina.com/OncologyPanel.
For Research Use Only. Not for use in diagnostic procedures.
About Illumina, Inc.
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as the global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture and other emerging segments. To
learn more, visit www.illumina.com and follow
@illumina.
Forward-Looking Statements
This release may contain forward-looking statements that involve
risks and uncertainties. Important factors that could cause actual
results to differ materially from those in any forward-looking
statements are detailed in our filings with the Securities and
Exchange Commission, including our most recent filings on Forms
10-K and 10-Q, or in information disclosed in public conference
calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date
of this release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150929005580/en/
Illumina, Inc.Investors:Rebecca
Chambers858-255-5243rchambers@illumina.comorMedia:Mina
Nicoletti858-882-6822pr@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2023 to Apr 2024